1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Imricor Medical Systems, Inc.

Imricor Medical Systems, Inc.

IMR.AX
Imricor Medical Systems, Inc.AU flagAustralian Securities Exchange
1.98
AUD
-0.01
- -
494.04MMarket Cap
Imricor Medical Systems, Inc.
IMR.AX
(Australian Securities Exchange)

Recent

price

1.98

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
0.01
0.01
0.01
0.01
- -
- -
- -
Revenue per Share
- -
-0.21
-0.11
-0.15
-0.12
-0.14
-0.13
- -
Basic EPS, GAAP
- -
-0.01
-0.01
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.11
0.25
0.17
0.05
-0.05
-0.03
- -
Book Value per Share
- -
0.11
0.25
0.17
0.05
-0.05
-0.03
- -
Tangible Book Value per Share
- -
62
114
135
150
162
224
- -
Basic Weighted Avg Shares
- -
1
1
1
1
1
1
- -
Sales/Revenue/Turnover
- -
-1,993.19
-1,780.9
-3,022.44
-2,205.25
-2,855.14
-1,778.53
-8,081.95
Operating Margin (%)
- -
- -
1
1
1
1
1
1
Depreciation Expense
- -
-13
-12
-20
-17
-23
-30
-25
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-2,078.14
-1,772.6
-2,834.05
-2,126.96
-3,675.61
-3,094.86
-8,661.57
Profit Margin (%)
12
5
27
20
8
-1
16
26
Working Capital
1
- -
1
1
4
10
21
14
LT Debt
13
7
29
22
8
-9
-7
12
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-129.68
-69.44
-77.06
-116.05
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-115.44%
-256.21%
Free Cash Flow
- -
61.66%
456.95%
Net Income, GAAP
- -
18.67%
-14.73%
Sales/Revenue/Turnover
- -
-4.37%
-69.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.14
2024
- -
- -
- -
- -
-0.13
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
LUMITO (LUMITO.ST)
i-SENS, Inc. (099190.KQ)
Shanghai United Imaging Healthcare Co., Ltd. (688271.SS)
PZ Cormay S.A. (CRM.WA)
Dermisonics, Inc. (DMSI)
INSPECS Group plc (SPEC.L)
Business
Imricor Medical Systems, Inc. (ASX:IMR) develops, manufactures and sells innovative magnetic resonance imaging (MRI)-compatible medical devices for cardiac catheter ablation procedures in interventional cardiac magnetic resonance (iCMR) labs. Founded in 2006 and headquartered in Burnsville, Minnesota, the company offers the Vision-MR Ablation Catheter 2.0, a patented device for real-time MRI-guided ablation approved in the European Union for treating type 1 atrial flutter; the Vision-MR Diagnostic Catheter; the Advantage-MR EP Recorder/Stimulator System, an electrophysiology amplifier, recording system and cardiac stimulator; the NorthStar Mapping System; and the Vision-MR Dispersive Electrode, along with additional consumables and capital equipment for hospitals and clinics. Imricor generates revenue primarily from Europe, followed by the Middle East and the United States, and collaborates with MRI vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH to install iCMR labs worldwide. In June 2025, the company launched the Vision-MR Ablation Catheter 2.0 and Vision-MR Diagnostic Catheter across Europe; in May 2025, procedures commenced at Semmelweis University; in April 2025, Imricor initiated the VISABL-VT clinical trial for ischemic ventricular tachycardia; and in July 2024, it completed a A$35 million two-tranche placement led by Canaccord Genuity, with ongoing U.S. trials including the first patient treated at Johns Hopkins in August 2024 under the VISABL-AFL study.